Role of subcutaneous formulation of trastuzumab in the treatment of patients with HER2-positive breast cancer

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Baselga J, Cortes J, Kim SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366, 109–119 (2012).
  Medline CASGoogle Scholar
• 2 Pivot X, Romieu G, Debled M et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised Phase 3 trial. Lancet Oncol. 14, 741–748 (2013).• The PHARE trial failed to demonstrate noninferiority of 6 compared with 12 months trastuzumab regimen in the adjuvant setting.
  Medline CASGoogle Scholar
• 3 Melichar B, Plebani M. Targeted therapy for HER2: personalized medicine for her, too. Clin. Chem. Lab. Med. 50, 1–4 (2012).
  Medline CASGoogle Scholar
• 4 von Minckwitz G, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J. Clin. Oncol. 27, 1999–2006 (2009).
  Medline CASGoogle Scholar
• 5 Blackwell KL, Burstein HJ, Storniolo AM et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: Final results from the EGF104900 study. J. Clin. Oncol. 30, 2585–2592 (2012).
  Medline CASGoogle Scholar
• 6 Weinblatt ME, Schiff M, Valente R et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis. Arthritis Rheum. 65, 28–38 (2013).
  Medline CASGoogle Scholar
• 7 Mathijssen RHJ, de Jong FA, Van der Bol JM, Verweij J, Sparreboom A. Flat-fixed dosing versus body surface area-based dosing of anticancer drugs in adults: does it make a difference? Oncologist 12, 913–923 (2007).
  MedlineGoogle Scholar
• 8 Bowen M, Armstrong N, Maa YF. Investigating high-concentration monoclonal antibody powder suspension in nonaqueous suspension vehicles for subcutaneous injection. J. Pharm. Sci. 101, 4433–4443 (2012).
  Medline CASGoogle Scholar
• 9 Shpilberg O, Jackish C. Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase. Br. J. Cancer 109, 1556–1561 (2013).• Summarizes current data on hylauronidase as well as on subcutaneous rituximab and trastuzumab.
  Medline CASGoogle Scholar
• 10 Bilous M, Morey AL, Armes JE et al. Assessing HER2 amplification in breast cancer: findings from the Australian In situ Hybridization Program. Breast Cancer Res. Treat. 134, 617–624 (2012).
  Medline CASGoogle Scholar
• 11 Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39–51 (2007).• Very instructive summary of the mechanism of action of trastuzumab.
  Medline CASGoogle Scholar
• 12 Carter P, Presta L, Gorman CM et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl Acad. Sci. USA 89, 4285–4289 (1992).
  Medline CASGoogle Scholar
• 13 Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin. Ther. 21, 309–318 (1999).
  Medline CASGoogle Scholar
• 14 Garnock-Jones KP, Keating GM, Scott LJ. Trastuzumab. A review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. Drugs 70, 215–239 (2010).
  Medline CASGoogle Scholar
• 15 Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann. Oncol. 18, 977–984 (2007).
  Medline CASGoogle Scholar
• 16 Boekhout AH, Beijnen JH, Schellens JHM. Trastuzumab. Oncologist 16, 800–810 (2011).
  Medline CASGoogle Scholar
• 17 Arnould L, Gelly M, Penault-Llorca F et al. Trastuzumab-based treatment of HER2-positive breast cancer an antibody-dependent cellular cytotoxicity mechanism? Br. J. Cancer 94, 259–267 (2006).
  Medline CASGoogle Scholar
• 18 Musolino A, Naldi N, Bortesi B et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER2/neu-positive metastatic breast cancer. J. Clin. Oncol. 26, 1789–1796 (2008).
  Medline CASGoogle Scholar
• 19 Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719–726 (2002).
  Medline CASGoogle Scholar
• 20 Leveque D, Gigou L, Bergerat P. Clinical pharmacology of trastuzumab. Curr. Clin. Pharmacol. 3, 51–55 (2008).
  Medline CASGoogle Scholar
• 21 Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N. Engl. J. Med. 344, 783–792 (2001).
  Medline CASGoogle Scholar
• 22 Piccart-Gebhart MJ, Procter M, Sci M et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659–1672 (2005).
  Medline CASGoogle Scholar
• 23 Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673–1684 (2005).
  Medline CASGoogle Scholar
• 24 Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354, 809–820 (2006).
  Medline CASGoogle Scholar
• 25 Slamon D, Eirmann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365, 1273–1283 (2011).
  Medline CASGoogle Scholar
• 26 Wolff AC, Hammond EH, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch. Pathol. Lab. Med. 131, 18–43 (2007).
  Medline CASGoogle Scholar
• 27 Wynne C, Harvey V, Schwabe C, Waaka D, McIntyre C, Bittner B. Comparison of subcutaneous and intravenous administration of trastuzumab: a Phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer. J. Clin. Pharmacol. 53, 192–201 (2013).
  Medline CASGoogle Scholar
• 28 Wynne CJ, Ellis-Pegler RB, Waaka DS et al. Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy males. Cancer Chemother. Pharmacol. 72, 1079–1087 (2013).
  Medline CASGoogle Scholar
• 29 Bittner B, Richter WF, Hourcade-Potelleret F et al. Development of a subcutaneous formulation for trastuzumab – nonclinical and clinical bridging approach to the approved intravenous dosing regimen. Arzneimittelforschung 62, 401–409 (2012).• Describes the development of subcutaneous trastuzumab from laboratory bench to clinical trials.
  Medline CASGoogle Scholar
• 30 Ismael G, Hegg R, Muehlbauer S et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a Phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 13, 869–878 (2012).•• The HannaH trial established noninferiority of subcutaneous versus intravenous trastuzumab formulation.
  Medline CASGoogle Scholar
• 31 Chollet P, Amat S, Cure H et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br. J. Cancer 86, 1041–1046 (2002).
  Medline CASGoogle Scholar
• 32 Bear HD, Anderson S, Smith RE et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-27. J. Clin. Oncol. 24, 2019–2027 (2006).
  Medline CASGoogle Scholar
• 33 Machiavelli MR, Romero AO, Perez JE et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J. Sci. Am. 4, 125–131 (1998).
  Medline CASGoogle Scholar
• 34 Thomas E, Holmes FA, Smith TL et al. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J. Clin. Oncol. 22, 2294–2302 (2004).
  Medline CASGoogle Scholar
• 35 Kuerer HM, Newman LA, Smith TL et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J. Clin. Oncol. 17, 460–469 (1999).
  Medline CASGoogle Scholar
• 36 Liedtke C, Mazouni C, Hess KR et al. Response neoadjuvant therapy and long term survival in patients with triple negative breast cancer. J. Clin. Oncol. 26, 1275–1281 (2008).
  MedlineGoogle Scholar
• 37 von Minckwitz G, Untch M, Blohmer JU et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J. Clin. Oncol. 30, 1796–1804 (2012).
  MedlineGoogle Scholar
• 38 Montagna E, Bagnardi V, Rotmensz N et al. Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features. Breast Cancer Res. Treat. 124, 689–699 (2010).
  MedlineGoogle Scholar
• 39 Guiu S, Arnould L, Bonnetain F et al. Pathological response and survival after neoadjuvant therapy for breast cancer: a 30-year study. Breast 22, 301–308 (2013).
  MedlineGoogle Scholar
• 40 Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N. Engl. J. Med. 26, 2438–2441 (2012).
  Google Scholar
• 41 Pivot X, Gligorov J, Muller V et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 14, 962–970 (2013).•• The PrefHer trial is one of the first studies in medical oncology to focus on patient preference as the primary end point. It established that most patients strongly prefer subcutaneous versus intravenous trastuzumab.
  Medline CASGoogle Scholar
• 42 Melichar B. PrefHer: finally addressing the preferences of her, too. Lancet Oncol. 14, 914–915 (2013).
  MedlineGoogle Scholar
• 43 Baselga J, Bradbury I, Eidtmann H et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, Phase 3 trial. Lancet 379, 633–640 (2012).
  Medline CASGoogle Scholar
• 44 Rimawi MF, Mayer IA, Forero A et al. Multicenter Phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J. Clin. Oncol. 31, 1726–1731 (2013).
  Medline CASGoogle Scholar
• 45 Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366, 520–529 (2012).
  Medline CASGoogle Scholar
• 46 Yardley DA, Ismail-Khan RR, Melichar B et al. Randomized Phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J. Clin. Oncol. 31, 2128–2135 (2013).
  Medline CASGoogle Scholar
• 47 Samanta K, Nawaz S, Lord S, McNamara S, Diment V. Cost savings with Herceptin (trastuzumab) subcutaneous vs. intravenous administration: a time and motion study. Presented at: St. Gallen Breast Cancer Conference, 13th Primary Therapy of Early Breast Cancer Conference P282. St Gallen, Switzerland, 12–16 March 2013.
  Google Scholar